Nabi
Rockville, MD, US· latest recorded location
NABI is named on 12 US grants and 2 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 12
- Published applications
- 2
- Inventors
- 12
- Granted in 2026 so far
- 0
- Most recent grant
- 29 Jun 2004
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 2 |
| 2003 | 2 | 0 |
| 2004 | 2 | 0 |
By publication year.
Technology areas
Share of 14 documents
- A61KMedicines and medical preparations13
- A61PTherapeutic uses of medicines11
- C07KPeptides11
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests6
- G01NInvestigating or analysing materials by determining their chemical or physical properties5
- C07HSugars2
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition2
Recent patents
- Enterococcus antigens and vaccines29 Jun 2004US 6,756,361 B1
- Ring-expanded nucleosides and nucleotides13 Jan 2004US 6,677,310 B1
- Staphylococcus aureus antigen-containing whole cell vaccine25 Mar 2003US 6,537,559 B2
- Hapten-carrier conjugates for treating and preventing nicotine addiction11 Feb 2003US 6,518,031 B2
- Compositions of β-glucans and specific IGIV12 Mar 2002US 6,355,625 B1
Most cited
By later US patents
- Staphylococcus aureus antigen-containing whole cell vaccine52US 6,294,177 B12001
- Staphylococcus aureus B-linked hexosamine antigen42US 5,770,208 A1998
- Hapten-carrier conjugates for treating and preventing nicotine addiction42US 6,232,082 B12001
- Type I surface antigen associated with staphylococcus epidermidis25US 5,866,140 A1999
- Ring-expanded nucleosides and nucleotides20US 5,843,912 A1998